Clinical Trial Update: [18F]Fluciclatide PET Imaging of Pazopanib Response [Phase 2]

View source ↗

Summary

Phase 2 trial using [18F]Fluciclatide PET imaging to assess Pazopanib response in kidney neoplasms has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Neoplasm

Drugs mentioned

• Pazopanib (Votrient) (Pazopanib)

Snippet

Sponsor: Asan Medical Center | Conditions: Kidney Neoplasm | Phase 2 | Status: TERMINATED